Adamas Pharma Announces Issuance Of Six Additional US Patents - Quick Facts

(RTTNews) - Adamas Pharmaceuticals, Inc. (ADMS) announced the issuance of six additional US patents, bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.

Gregory Went, Adamas' CEO and a co-inventor on these patents, said: "This additional series of patents is based upon patent applications initially filed in 2004. Importantly, these patents cover product candidates that we believe would enable once-daily dosing over a wide range of strengths and formulations, as well as combination formulations."